FDA clearance for Surgiphor 1000mL strengthens BDX's product pipeline and fundamental growth outlook. Technicals remain aligned with prior bullish bias.

Market sentiment stays positive as bullish headlines dominate, including new FDA approval and outperforming Dow narratives. No material shift from prior strongly bullish stance.

Regulatory approval lowers near-term risk and supports long-term growth, though valuation may already reflect optimism. Maintaining bullish outlook with elevated confidence.

Data signals remain consistent with prior bullish patterns following positive FDA catalyst. No technical reversal observed, maintaining positive bias.